Abstract
Objective:The aim of this study is to find out whether the pseudotumoral lesions (inflammation/granuloma) seen at the follow-up cystoscopy performed three to six months after transurethral resection of primary stage T1 grade 3 bladder tumor and instillations of BCG therapy might have some prognostic value as far as recurrence and/or long term progression are concerned.Material and methods:From the first group of one hundred and thirteen patients with primary stage of T1 grade 3 bladder tumor treated with 81 mg of BCG Connaught (weekly/during six weeks), those with recurrent tumor at the 3rd and 6th month were excluded, so we evaluated 99 patients. We identified 13 patients with cystoscopically pseudotumoral lesions. Results:of the 13 cystoscopically pseudotumoral lesions, we observed recurrence in two cases (15%), while among the rest of the 86 patients, we observed 22 recurrences (26%) (p = 0.9; not significant). Concerning progression, eight cases were reported out of 86 patients (9%) within the cistocopically normal group. No cases of progression were reported among the 13 patients with cystoscopically pseudotumoral lesions. This difference was not statistically significant (p = 0.5).Conclusions:The patients with cystoscopically pseudotumoral lesions (inflammation/granuloma) are a reduced group (13%) with less tendency to recurrence and without progression, even though this relationship is not significant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Martínez Piñeiro JA. Bacillus Calmette-Güerin versus doxor-ubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J Urol 1990; 143: 502
Millán F, Chéchile G, Salvador J et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73
Böhle A. For the EBIN group. BCG's mechanism of action-increasing our understanding. Eur Urol 2000; 37(suppl 1): 1
El-Demiry MI, Smith G, Ritchie WS et al. Local inmune responses after BCG treatment for carcinoma in situ. Br J Urol 1987; 60: 543
Pieras E, Palou J, Rodríguez-Villamil L et al. Seguimiento cistoscópico de los tumors vesicales G3T1 iniciales tratados con BCG. Arch Esp Urol 2001; 54(3): 211
Shapiro A, Lijovetz G, Pode D. Changes of the mucosal archi-tecture and of urine cytology during BCG treatment. World J Urol 1988; 6: 61
Oates RD, Stilmant MM, Freedlund MC, Siroky MB. Granu-lomatous prostatitis following Bacillus Calmette Guérin immunotherapy of bladder cancer. J Urol 1988; 140: 751
Mukamel E, Konichezky M, Engelstein D et al. Clinical and pathologycal findings in prostates following intravesical Bacillus Calmette Guérin instillations. J Urol 1990; 144: 1399
Teppema JS, De Boer EC, Steerenberg PA, Van Der Meijden APM. Morphological aspects of the interaction of Bacillus Calmette Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol Res 1992; 20: 219–228
De Reijke TM, De Boer EC, Hein Kurth K, Schamhart DHJ. Urinary Cytokines during intravesical Bacillus Calmette Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155: 477
Thalmann GN, Sermier A, Rentsch C et al. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with Bacillus Calmette Guérin. J Urol 2000; 164: 2129
Bassi P, Milani C, Meneghini A et al. Clinical value of patho-logic changes after intravesical BCG therapy of superficial bladder cancer. Urology 1992; 40: 175
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180
Herr HW, Pinsky CM, Whitmores WF et al. Experience with intravesical Bacillus Calmette Guérin therapy of superficial bladder tumors. Urology 1985; 25(2): 119
Schellhammer PF, Ladaga LE, Fillion MB. Bacillus Calmette Guérin for superficial transitional cell carcinoma of the bladder. J Urol 1986; 135: 261
Kelley DR, Haaff EO, Becich M et al. Prognostic value of purified derivate skin test and granuloma formation in patients treated with intravesical Bacillus Calmette Guérin. J Urol 1986; 135: 268
Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL.Prognostic factors in patients treated with intravesical Bacillus Calmette Guérin for superficial bladder cancer. J Urol 1988; 139: 941
Bowyer L, Hall RR, Reading J, Marsch MM. The persistence of bacille Calmette Guérin in the bladder after intravesical treatment for bladder cancer. Br J Urol 1995; 75: 188
Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000; 37(suppl 1): 9
Jackse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?J Urol 1987; 137: 39
Herr HW, Badalament RA, Amato DA et al. Superficial bladder cancer treated with Bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22
Palou J, Rosales A, Millán F et al. Clinical prognostic factors of recurrence and progression in TCC stage T1G3 treated with BCG. B J U Int 2000; 86(Suppl 3): 3
Hurle R, Losa A, Ranieri A et al. Low dose Pasteur Bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996; 156: 1602
Hurle R, Losa A, Manzetti A, Lembo A. Intravesical Bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258
Lebret T, Gaudez F, Hervé JM et al. Low-Dose BCG instilla-tions in the treatment of Stage T1 grade 3 bladder tumors: recurrence, progression and success. Eur Urol 1998; 34: 67
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pieras-Ayala, E., Palou-Redorta, J., Tornero-Ruiz, J. et al. Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol 33, 469–472 (2001). https://doi.org/10.1023/A:1019533806868
Issue Date:
DOI: https://doi.org/10.1023/A:1019533806868